Seller record · Telehealth service

Independent Wellness

Fails 3 of 8 criteria. S4, compounding disclosure: The pricing page says the semaglutide prescribed through the program is FDA-approved for other uses but not specifically for weight loss, on the page that sells it as a compounded product. The answers elsewhere state that compounded medications are not FDA-approved. 2 more criteria also fail; see the table below.

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth weight loss practice in which one board-certified nurse practitioner sees every patient, selling compounded semaglutide and tirzepatide by injection or oral drops in 20 states, with a discounted first month and a fixed monthly price after it. It names three dispensing pharmacies with addresses and prints no company address.

Operating entity No legal entity name appears in the footer, on the contact page, in the privacy policy or in the disclaimer, which name the company only as Independent Wellness, and the site publishes no terms of use.

Dispositions

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

Products shown on the seller's own pages at the recorded date: compounded semaglutide injections, compounded tirzepatide injections, compounded oral semaglutide drops, compounded oral tirzepatide, Ozempic, Zepbound, GLP-1 microdosing, NAD, glutathione, sermorelin.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.